The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst
: Congratulations on all the progress this year and in the quarter. I'm going to ask on Zepzelca. Can you talk about your expectations
for the ATLANTIS trial? And what are your range of threshold for a successful outcome here? I know in the past, you've talked about
this trial serving as a confirmatory trial even if it's not stacked. So can you just elaborate a little bit more around that scenario? And
then if ATLANTIS is not confirmatory, how soon should we expect you to begin entering confirmatory trial of the monotherapy?
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: On Xywav, and congrats on that approval, how do you expect payers will handle the 2 products with pricing at parity? Have you
been preparing payers for this transition from Xyrem? And what prelaunch activities are you planning on doing on the low-sodium
benefits to help facilitate uptake and to try and get to the majority of that switch by 2023 that Dan talked about?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 04, 2020 / 8:30PM, JAZZ.OQ - Q2 2020 Jazz Pharmaceuticals PLC Earnings Call
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: Okay. And other prelaunch activities, I don't know if you could comment, on that in terms of low-sodium benefit?
Question: Gregory B. Gilbert - SunTrust Robinson Humphrey, Inc., Research Division - Analyst
: It's Truist at this point. Looks like WAKIX is off to a decent start, Bruce, according to an S-1. I was curious if you or your teammates
had any updated thoughts on where or how that product is being used. And do you see the potential addition of cataplexy to its
label should that occur as a meaningful change to the competitive profile?
Question: Gregory B. Gilbert - SunTrust Robinson Humphrey, Inc., Research Division - Analyst
: And Bruce, no hard feelings about the name. You have a lot of new names to keep up with.
| 
